Press Release

ONCOLYS BIOPHARMA INC. (TSE Mothers: 4588)

25 May 2016

**OBP-1101 (TelomeScan F35) Research on Pancreatic Cancer Received the Award from the Japanese Society for Advancement of Surgical Techniques**

**Tokyo, JAPAN:** Oncolys BioPharma is pleased to announce that one of our outstanding research collaborators, Dr. Tanemura (Osaka Police Hospital) has received an award from the Japanese Society for Advancement of Surgical techniques (JSAST), a long-established and one of the most prestigious research society specialized in surgical techniques in Japan, in connection with his research on pancreatic cancer using OBP-1101 (TelomeScan F35).

The aim of Dr. Tanemura’s research was to evaluate the possible association of Circulating Tumor Cells (CTC) in the blood with metastases and recurrences of pancreatic cancer using OBP-1101 which replicates and produces fluorescence specifically in telomerase-positive cancer cells.

Pancreatic cancer patients are often found in the advanced tumor stage when diagnosed, and it is known that they have relatively high postoperative recurrence rate. Improving their prognosis as well as achieving better treatment outcomes by defining the mechanism of metastases and recurrences of pancreatic cancer are a serious challenge in the clinical settings.

Dr. Tanemura used OBP-1101 in his study to evaluate the efficacy of neoadjuvant chemo-radiotherapy (NACRT) for pancreatic cancer patients and to analyse a correlation between CTCs and relevant patients’ prognosis. The results showed that pre-NACRT CTC-positive patients often had an increased number of CTCs after receiving NACRT, and even after a resection of pancreas cancer cells/tissues they remained CTC-positive. It was also understood that the said patient group has a higher recurrence risk, including hepatic metastasis cases, from an early postoperative period. On the other hand, among patients without NACRT, many pre/post-surgery CTC-negative cases or those CTC-negative after a resection, showed no cancer recurrence.

“Based on outcomes of the study, we believe that a CTC analysis using OBP-1101 has a good potential to be applied to clinical settings as an excellent biomarker, to assess therapeutic efficacy and for prognosis determination in pancreatic cancer patients.” said Dr. Masahiro Tanemura, MD, PhD, from the Department of Gastroenterological Surgery, Osaka Police Hospital. “Given the current clinical
environments where pancreatic cancer patients mostly undergo pre-surgical treatments, we believe that CTC detection using OBP-1101 pre-operations to test the presence or absence of CTC will help doctors and patients to decide more appropriate treatment approaches, which will consequently result in improved therapeutic efficacy.”

“We are very much pleased to receive such good news that Dr. Tanemura’s research won a prestigious award from the JSAST. We look forward to further progress in adoption of OBP-1101 in clinical settings in the future, in order for us to contribute to an improved pancreatic cancer treatment outcomes for doctors and patients” stated Yasuo Urata, CEO, Oncolys BioPharma Inc.

The details of the award presentation ceremony are as below:

The 70th Meeting of the Japanese Society for Advancement of Surgical Techniques  
Date: Saturday 21 May, 2016 (award ceremony and presentation started at 12:40)  
Theme: “Application of next generation CTC detection virus TelomeScan F35 - Mechanism of peritoneal metastases and recurrences of gastric and pancreatic cancer, defining treatment refractoriness of patients and possible breakthrough”  
Research Representative: Dr. Masahiro Tanemura  
Title & Affiliation: Chairperson, Department of Gastroenterological Surgery, Osaka Police Hospital Professor, Graduate School of Medicine, Osaka University  
HP: http://square.umin.ac.jp/jsast/

**About Oncolys BioPharma Inc.:**

Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, OBP-301 (Telomelysin™), is based on replication-competent oncolytic virus, and is being tested in Phase I/II clinical trial in Asia, for various solid tumors. A novel cancer diagnostic product, OBP-401 (TelomeScan), is expected to be effective in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Festinavir) for infectious diseases, which has completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS. OBP-601 is a novel NRTI with highly promising safety and resistance profiles. For more additional information, please visit [www.oncolys.com](http://www.oncolys.com)

<table>
<thead>
<tr>
<th>Oncolys BioPharma Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mie Yamazaki</td>
</tr>
<tr>
<td>Investor Relations &amp; Corporate Communications</td>
</tr>
<tr>
<td>Tel: +81 (0) 5472 1578</td>
</tr>
<tr>
<td>Email: <a href="mailto:yamazaki@oncolys.com">yamazaki@oncolys.com</a></td>
</tr>
</tbody>
</table>